Q-omics provides the consensus-scored RAD51C profile across patient tissues and cancer cell-line models. RAD51C expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RAD51C is differentially expressed in 14, with the highest sampling consensus in KICH. Additionally, RAD51C RNA expression shows 19,557 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and KICH as cancer lineages where RAD51C shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RAD51C — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RAD51C survival associations across molecular data types. RAD51C RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RAD51C RNA expression–survival associations across cancer types. High RAD51C expression shows unfavorable associations in ACC, LIHC, KICH, KIRP and BLCA, but favorable associations in KIRC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for RAD51C RNA expression.
This table summarizes RAD51C tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 4. The strongest signals are observed in LIHC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for RAD51C. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RAD51C shows lower tumor expression in KICH and higher tumor expression in LIHC, COAD, LUAD, HNSC and LUSC. The KICH box plot shows higher RAD51C RNA expression in normal versus tumor tissue (log2 FC = −1.479, t-test p < 0.001).
This table shows molecular features associated with RAD51C in patient tissues and cancer cell lines. In patient samples, RAD51C shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, RAD51C RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
